


| Key | % Net Assets |
|---|---|
| 4.6% | |
| 4.5% | |
| 4.3% | |
| 4.2% | |
| 82.4% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 4.6% |
| Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
| Vodafone Group | 4.3% |
| BP | 4.2% |
| Vodafone Group | 4.2% |
| British American Tobacco | 3.4% |
| Aberforth UK Small Companies | 3.2% |
| HSBC Holdings PLC (UK Reg) | 2.9% |
| BG Group | 2.3% |
| AstraZeneca | 2.3% |
No asset data available.
| Date | 20-Aug-2025 |
|---|---|
| NAV | 184.20p |
| Currency | GBP |
| Change | 0.20p |
| % | 0.11% |
| YTD change | 20.40p |
| YTD % | 12.45% |
| Fund Inception | 31/07/1998 |
|---|---|
| Fund Manager | HSBC Multimanager |
| TER | 1.65 (15-Jan-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £500 |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.05 |
You are here: research